The addition of cetuximab to cisplatin doubled the overall response rate and prolonged OS compared with cisplatin alone in patients with metastatic triple-negative breast cancer, according to results of a randomized phase 2 study.
However, the combination treatment did not meet the predetermined response rate of more than 20%.
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.